Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
-
Narrated by:
-
By:
About this listen
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet